Although the study was conducted in a limited number of cases, the overexpression of B4GALT1 in IPF observed in our patients is a novel finding and it could represent a new diagnostic marker, potentially usable as a therapeutic target for a disease still burdened with an unfavorable prognosis. Here, B4GALT1 is linked to idiopathic pulmonary fibrosis.